Zacks: Analysts Anticipate Jazz Pharmaceuticals PLC (JAZZ) Will Announce Quarterly Sales of $420.76 Million
Equities research analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to report sales of $420.76 million for the current quarter, according to Zacks. Six analysts have provided estimates for Jazz Pharmaceuticals PLC’s earnings, with the lowest sales estimate coming in at $416.35 million and the highest estimate coming in at $426.72 million. Jazz Pharmaceuticals PLC reported sales of $374.18 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 12.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 14th.
On average, analysts expect that Jazz Pharmaceuticals PLC will report full year sales of $420.76 million for the current year, with estimates ranging from $1.62 billion to $1.67 billion. For the next fiscal year, analysts forecast that the business will post sales of $1.90 billion per share, with estimates ranging from $1.80 billion to $2.06 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). The company had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. Jazz Pharmaceuticals PLC’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.67 EPS.
JAZZ has been the subject of several research analyst reports. Wells Fargo & Company reiterated an “outperform” rating and issued a $177.00 price objective (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. BidaskClub downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $197.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, June 27th. Goldman Sachs Group, Inc. (The) initiated coverage on Jazz Pharmaceuticals PLC in a report on Thursday, September 28th. They issued a “neutral” rating and a $165.00 price objective for the company. Finally, Zacks Investment Research upgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price objective for the company in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $179.79.
In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total value of $150,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $160.00, for a total value of $732,800.00. Following the completion of the transaction, the executive vice president now directly owns 32,322 shares in the company, valued at $5,171,520. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,097 shares of company stock worth $1,398,423. 4.30% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Somerset Trust Co lifted its holdings in Jazz Pharmaceuticals PLC by 0.4% in the 2nd quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock worth $497,000 after purchasing an additional 14 shares in the last quarter. World Asset Management Inc lifted its holdings in Jazz Pharmaceuticals PLC by 1.9% in the 2nd quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock worth $224,000 after purchasing an additional 27 shares in the last quarter. Profund Advisors LLC lifted its holdings in Jazz Pharmaceuticals PLC by 1.3% in the 2nd quarter. Profund Advisors LLC now owns 2,915 shares of the specialty pharmaceutical company’s stock worth $453,000 after purchasing an additional 38 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its holdings in Jazz Pharmaceuticals PLC by 0.8% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 6,550 shares of the specialty pharmaceutical company’s stock worth $951,000 after purchasing an additional 50 shares in the last quarter. Finally, Toronto Dominion Bank lifted its holdings in Jazz Pharmaceuticals PLC by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 81 shares in the last quarter. 87.82% of the stock is currently owned by institutional investors.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 140.50 on Tuesday. The company has a market cap of $8.44 billion, a price-to-earnings ratio of 21.64 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The company’s 50-day moving average is $148.43 and its 200 day moving average is $151.54.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Jazz Pharmaceuticals PLC (JAZZ) Will Announce Quarterly Sales of $420.76 Million” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/17/zacks-analysts-anticipate-jazz-pharmaceuticals-plc-jazz-will-announce-quarterly-sales-of-420-76-million.html.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.